Sofgen Pharma S.A PROCF
0.00
0.00
NaN
as of 24 Sep
- Market cap
- $114.0M
- P/E
- 0.0×
Follow PROCF
| Dec '24 | Dec '23 | Dec '22 | Sep '22 | Dec '21 | Sep '21 | Dec '20 | Sep '20 | Dec '19 | Sep '19 | |
|---|---|---|---|---|---|---|---|---|---|---|
P/E ratio |
5.76 | 10.54 | 13.38 | 11.57 | 0.00 | 0.00 | 0.00 | — | 985.00 | — |
P/S ratio |
0.56 | 1.02 | 1.17 | 1.63 | 2.34 | 1.85 | 0.00 | — | 0.00 | — |
P/FCF ratio |
3.16 | 5.78 | 0.00 | 0.00 | 70.51 | 0.00 | 0.00 | — | 0.00 | — |
P/Operating CF |
6.44 | 11.78 | (72.80) | 122.96 | (70.14) | 28.64 | (1.75) | — | (142.51) | — |
P/B ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 28.19 | 0.00 | — | 9.85 | — |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 279.51 | 0.00 | — | 9.85 | — |
EV/Sales |
1.26 | 1.72 | 1.83 | 2.16 | 2.80 | 2.10 | 0.00 | — | 0.00 | — |
EV/EBITDA |
5.91 | 8.08 | 27.63 | 10.62 | 13.40 | 3.70 | 1.93 | — | 0.00 | — |
EV/Operating CF |
4.95 | 6.77 | 47.37 | 111.55 | 30.74 | 53.21 | (1,855.61) | — | (132.69) | — |
EV/FCF |
7.13 | 9.74 | (43.61) | (49.59) | 84.48 | (666.08) | (71.16) | — | (132.69) | — |
Quick Ratio |
0.26 | 0.34 | 0.39 | 0.53 | 1.01 | 1.01 | 0.42 | 6.61 | — | 0.12 |
Current Ratio |
0.52 | 0.64 | 0.72 | 0.81 | 1.59 | 1.59 | 0.77 | 7.28 | — | 0.12 |
Net Debt/EBITDA |
(7.21) | 3.29 | 9.88 | 4.27 | 2.22 | 2.12 | 5.92 | 1.10 | 0.00 | 1.83 |
Debt/Assets |
66.83% | 67.88% | 69.23% | 62.13% | 56.65% | 54.83% | 132.15% | 0.00% | 0.00% | 0.00% |
Debt/Equity |
(5.28) | (435.78) | (8.25) | (303.86) | (6.83) | (6.77) | (1.87) | 0.00 | — | 0.00 |
Asset Turnover |
0.85 | 0.93 | 0.89 | 0.89 | 0.89 | 1.00 | 1.18 | 0.00 | 2,694.25 | 0.00 |
Operating CF/Net income |
(1.29) | 2.67 | 0.43 | 0.10 | (0.37) | (0.20) | (6.86) | 0.06 | (4.02) | 1.00 |
Capex/Depreciation |
(1.25) | (1.80) | (1.93) | 0.00 | (1.57) | 0.00 | (1.05) | — | (0.74) | 0.00 |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| 258.60% | (213.06%) | (189.76%) | (216.59%) | 266.34% | 69.07% | 8.37% | (501.00%) | 0.00% | 562.96% | |
| (15.45%) | 8.82% | 8.00% | 9.22% | (21.83%) | (24.55%) | (3.72%) | (12.40%) | (14,108.67%) | (6.30%) | |
ROIC |
(17.51%) | 15.21% | 2.71% | 0.00% | 29.10% | 0.00% | 18.23% | (13.41%) | 0.00% | 0.00% |
Return on Tangible Assets |
64.76% | (60.27%) | (99.25%) | 101.17% | (55.20%) | (45.25%) | (67.80%) | (1,382.41%) | 0.00% | 7.47% |
Average Days of Receivables |
76.48 | 107.54 | 96.33 | 136.47 | 104.62 | 105.65 | 106.25 | — | 0.00 | — |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | — | 0.00% | 0.00% |
Selling, General and Administrative Expense of Revenue |
59.67% | 45.63% | 49.03% | 48.66% | 40.33% | 40.33% | 38.69% | — | 44.66% | — |
Intangible Assets out of Total Assets |
0.07 | 0.09 | 0.09 | 0.08 | 0.08 | 0.08 | 0.10 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | — | 0.00% | — |
Graham Net Nets |
(0.84) | (0.46) | (0.42) | (0.25) | (0.21) | (0.12) | (8.26) | — | (3.97) | — |
Graham Number |
— | 0.00 | 0.00 | 0.00 | 3.01 | 0.00 | 41.18 | — | 0.00 | — |
Earnings Yield |
17.36% | 9.49% | 7.47% | 8.64% | (10.54%) | (24.88%) | (14.23%) | — | 0.10% | — |
Free Cash Flow Yield |
31.67% | 17.31% | (3.57%) | (2.67%) | 1.42% | (0.17%) | (14.13%) | — | (0.73%) | — |
Revenue per Share |
3.73 | 4.20 | 3.99 | 4.05 | 4.17 | 3.63 | 3.41 | 0.00 | 3.34 | 0.00 |
Operating CF per Share |
0.88 | 1.07 | 0.15 | 0.04 | 0.38 | 0.18 | 0.74 | (0.15) | 0.70 | 0.00 |
Capex per Share |
(0.25) | (0.32) | (0.32) | 0.00 | (0.24) | 0.00 | (0.18) | 0.00 | (0.12) | 0.00 |
Free Cash Flow per Share |
0.63 | 0.74 | (0.17) | 0.04 | 0.14 | 0.18 | 0.56 | (0.15) | 0.58 | 0.00 |
Cash per Share |
0.30 | 0.24 | 0.43 | 0.43 | 0.73 | 0.64 | 0.04 | 0.19 | 0.00 | 0.01 |
Shareholders Equity per Share |
(0.52) | (0.01) | (0.37) | (0.01) | (0.39) | (0.33) | (2.62) | 1.00 | 0.00 | 0.00 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
(0.52) | (0.01) | (0.37) | (0.01) | (0.39) | (0.33) | (2.62) | 1.00 | 0.00 | 0.00 |
Free Cash Flow |
63.46 | 74.84 | (16.89) | 4.08 | 13.57 | 19.88 | 54.41 | (0.77) | 56.19 | (0.02) |
Working Capital |
(199.18) | (157.92) | (106.98) | (70.93) | 110.10 | 110.10 | (54.93) | 0.91 | — | (0.20) |
Capital Expenditures |
(24.97) | (32.79) | (32.44) | (31.57) | (23.73) | (24.52) | (17.29) | — | (12.11) | 0.00 |
Net Current Asset Value |
(247.03) | (197.59) | (200.36) | (164.62) | (202.42) | (202.42) | (429.51) | (196.32) | — | (0.20) |
EV/EBIT |
7.40 | 10.12 | 75.06 | 12.65 | 16.27 | 33.16 | 38.55 | — | 0.00 | — |
Capex to Sales |
0.07 | 0.08 | 0.08 | 0.00 | 0.06 | 0.00 | 0.05 | — | 0.04 | 0.00 |
Net Profit Margin |
(18.27%) | 9.52% | 8.96% | 10.38% | (24.62%) | (24.62%) | (3.15%) | 0.00% | (5.24%) | 0.00% |
Price to Operating Income |
3.28 | 6.00 | 48.22 | 9.54 | 13.58 | 3.46 | 0.20 | — | 0.00 | — |
| Other line items | ||||||||||
Depreciation/Fixed assets |
0.21 | 0.20 | 0.24 | 0.15 | 0.21 | 0.13 | 0.23 | — | 0.00 | 0.00 |
Cash ROIC |
(2.09%) | 4.84% | (17.63%) | (33.20%) | (11.95%) | (32.26%) | 0.61% | (13.01%) | 0.00% | (40.43%) |
Accounts Receivable Turnover |
3.68 | 3.66 | 3.11 | 3.03 | 3.47 | 3.81 | 0.00 | — | 0.00 | — |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 2.25 | 0.00 | 0.00 | 0.00 | — | 0.00 | — |
Inventory Turnover |
2.04 | 1.84 | 1.71 | 1.93 | 2.19 | 2.42 | 0.00 | — | 0.00 | — |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | 0.00 | — |
Days of Inventory on Hand |
153.24 | 200.06 | 216.65 | 207.48 | 166.59 | 166.59 | 167.41 | — | 0.00 | — |
Average Receivables |
101.59 | 115.64 | 129.84 | 135.36 | 118.02 | 107.54 | — | — | — | — |
Average Payables |
— | — | — | 75.82 | — | — | — | — | — | — |
Average Inventory |
89.18 | 100.79 | 98.30 | 88.13 | 79.43 | 71.86 | — | — | — | — |
Average Assets |
442.10 | 457.51 | 451.36 | 461.16 | 462.14 | 410.84 | 280.96 | 101.19 | 0.12 | 0.24 |
Average Common Equity |
(26.41) | (18.93) | (19.04) | (19.64) | (37.87) | (146.04) | (124.84) | 2.50 | — | 0.00 |
Columns are period end dates